DrugPatentWatch Database Preview
Investigational Drug Information for Penclomedine
Email this page to a colleague
What is the development status for investigational drug Penclomedine?
Penclomedine is an investigational drug.
There have been 7 clinical trials for Penclomedine.
The most recent clinical trial was a Phase 2 trial, which was initiated on September 1st 2013.
The most common disease conditions in clinical trials are Neoplasms, Lymphoma, and Neoplasms, Second Primary. The leading clinical trial sponsors are National Cancer Institute (NCI), DEKK-TEC, Inc., and Sidney Kimmel Comprehensive Cancer Center.
There are sixty-four US patents protecting this investigational drug and five hundred and seventy-five international patents.
Summary for Penclomedine
| US Patents | 64 |
| International Patents | 575 |
| US Patent Applications | 220 |
| WIPO Patent Applications | 111 |
| Japanese Patent Applications | 21 |
| Clinical Trial Progress | Phase 2 (2013-09-01) |
| Vendors | 13 |
Recent Clinical Trials for Penclomedine
| Title | Sponsor | Phase |
|---|---|---|
| DM-CHOC-PEN Plus Radiation for Brain Tumors | National Cancer Institute (NCI) | Phase 1 |
| DM-CHOC-PEN Plus Radiation for Brain Tumors | DEKK-TEC, Inc. | Phase 1 |
| Study of 4-Demethyl-4-cholesteryloxycarbonylpenclome (DM-CHOC-PEN) in Patients With Brain Tumors | Detroit Clinical Research Center, Farmington Hills, Lansing and Owasso, MI | Phase 2 |
Clinical Trial Summary for Penclomedine
Top disease conditions for Penclomedine
Top clinical trial sponsors for Penclomedine
US Patents for Penclomedine
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Penclomedine | ⤷ Sign up for a Free Trial | Methods and systems for predicting cancer outcome | H. Lee Moffitt Cancer Center and Research Institute, Inc. (Tampa, FL) University of South Florida (Tampa, FL) | ⤷ Sign up for a Free Trial |
| Penclomedine | ⤷ Sign up for a Free Trial | Dosage regimen for a PI-3 kinase inhibitor | NOVARTIS AG (Basel, CH) | ⤷ Sign up for a Free Trial |
| Penclomedine | ⤷ Sign up for a Free Trial | Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor | Novartis AG (Basel, CH) | ⤷ Sign up for a Free Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Penclomedine
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Penclomedine | European Patent Office | EP1894131 | 2025-02-25 | ⤷ Sign up for a Free Trial |
| Penclomedine | World Intellectual Property Organization (WIPO) | WO2005083128 | 2024-02-25 | ⤷ Sign up for a Free Trial |
| Penclomedine | World Intellectual Property Organization (WIPO) | WO2006093507 | 2024-02-25 | ⤷ Sign up for a Free Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
